Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 2, 2015, Pages 213-219

  Rzodkiewicz, Przemyslaw ^a,b   Gasinska, Emilia ^b   Maslinski, Slawomir ^b   Bujalska Zadrozny, Magdalena ^b  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

5 lipoxygenase inhibitor; Carrageenan; Esculetin; Hyperalgesia; Pain; Rat

Indexed keywords

ESCULETIN; LEUKOTRIENE B4; ZILEUTON; ANALGESIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; HYDROXYUREA; LIPOXYGENASE INHIBITOR; UMBELLIFERONE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HYPERALGESIA; INFLAMMATORY PAIN; MECHANICAL STIMULATION; MOUSE; NONHUMAN; PAIN; THERAPY EFFECT; THERMAL STIMULATION; ANALGESIA; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; MALE; METABOLISM; PAIN THRESHOLD; PROCEDURES; RAT;

ANALGESIA; ANALGESICS; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; DISEASE MODELS, ANIMAL; HYDROXYUREA; HYPERALGESIA; INFLAMMATION; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MALE; PAIN; PAIN THRESHOLD; RATS; UMBELLIFERONES;

EID: 84920923649     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12346     Document Type: Article

References (41)

1. Aley O, Levine JD. Contribution of 5- and 12-lipoxygenase products to mechanical hyperalgesia induced by prostaglandin E(2) and epinephrine in the rat. Exp. Brain Res. 2003; 148: 482-7.
2. 4 receptor on the dorsal root ganglion neurons in mice. Brain Res. Mol. Brain Res. 2005; 137: 263-6.
3. Levine JD, Lam D, Taiwo YO, Donatoni P, Goetzl EJ. Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid. Proc. Natl Acad. Sci. USA 1986; 83: 5331-4.
4. Singh VP, Patil CS, Kulkarni SK. Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats. Pharmacol. Biochem. Behav. 2005; 81: 433-9.
5. 2. J. Leukoc. Biol. 2008; 83: 122-30.
6. 4 produces hyperalgesia in humans. Prostaglandins 1985; 30: 791-7.
7. 4 in man. Allergy 1986; 41: 365-72.
8. Cortes-Burgos LA, Zweifel BS, Settle SL et al. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. Eur. J. Pharmacol. 2009; 617: 59-67.
9. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2003; 62: 501-9.
10. Bissonnette EY, Tremblay GM, Turmel V, Pirotte B, Reboud-Ravaux M. Coumarinic derivatives show anti-inflammatory effects on alveolar macrophages, but their anti-elastase activity is essential to reduce lung inflammation in vivo. Int. Immunopharmacol. 2009; 9: 49-54.
11. Neichi T, Koshihara Y, Murota S. Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochim. Biophys. Acta 1983; 753: 130-2.
12. Surse VM, Gupta J, Tikoo K. Esculetin induced changes in Mmp13 and Bmp6 gene expression and histone H3 modifications attenuate development of glomerulosclerosis in diabetic rats. J. Mol. Endocrinol. 2011; 46: 245-54.
13. Yun ES, Park SK, Kim BS et al. Determination of the esculetin contents of medicinal plants by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 2012; 26: 1247-51.
14. Huang HC, Lai MW, Wang HR, Chung YL, Hsieh LM, Chen CC. Antiproliferative effect of esculetin on vascular smooth muscle cells: Possible roles of signal transduction pathways. Eur. J. Pharmacol. 1993; 237: 39-44.
15. Lin WL, Wang CJ, Tsai YY, Liu CL, Hwang JM, Tseng TH. Inhibitory effect of esculetin on oxidative damage induced by t-butyl hydroperoxide in rat liver. Arch. Toxicol. 2000; 74: 467-72.
16. Pan SL, Huang YW, Guh JH, Chang YL, Peng CY, Teng CM. Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats. Biochem. Pharmacol. 2003; 65: 1897-905.
17. Wang C, Pei A, Chen J et al. A natural coumarin derivative esculetin offers neuroprotection on cerebral ischemia/reperfusion injury in mice. J. Neurochem. 2012; 121: 1007-13.
18. Chu CY, Tsai YY, Wang CJ, Lin WL, Tseng TH. Induction of apoptosis by esculetin in human leukemia cells. Eur. J. Pharmacol. 2001; 416: 25-32.
19. Subramaniam SR, Ellis EM. Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease. J. Neurosci. Res. 2013; 91: 453-61.
20. Watanabe K, Ito A, Sato T, Saito T, Hayashi H, Niitani Y. Esculetin suppresses proteoglycan metabolism by inhibiting the production of matrix metalloproteinases in rabbit chondrocytes. Eur. J. Pharmacol. 1999; 370: 297-305.
21. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E, Thornes RD. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab. Rev. 1990; 22: 503-29.
22. Okada Y, Miyauchi N, Suzuki K et al. Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Chem. Pharm. Bull. 1995; 43: 1385-7.
23. Meotti FC, Ardenghi JV, Pretto JB et al. Antinociceptive properties of coumarins, steroid and dihydrostyryl-2-pyrones from Polygala sabulosa (Polygalaceae) in mice. J. Pharm. Pharmacol. 2006; 58: 107-12.
24. Park SH, Sim YB, Kang YJ et al. Antinociceptive profiles and mechanisms of orally administered coumarin in mice. Biol. Pharm. Bull. 2013; 36: 925-30.
25. Miller TA, Ghosh J, Myers CE, Macdonald TL. 5-HETE congeners as modulators of cell proliferation. Bioorg. Med. Chem. Lett. 2000; 10: 2013-6.
26. Powell WS, Rokach J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog. Lipid Res. 2005; 44: 154-83.
27. Cunha TM, Verri WA Jr, Schivo IR et al. Crucial role of neutrophils in the development of mechanical inflammatory hypernociception. J. Leukoc. Biol. 2008; 83: 824-32.
28. 4 prevents articular incapacitation in rat zymosan-induced arthritis. Eur. J. Pharmacol. 2004; 497: 81-6.
29. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: Oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92: 3007-17.
30. Jain NK, Kulkarni SK, Singh A. Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals. Eur. J. Pharmacol. 2001; 423: 85-92.
31. 4 in radicular pain induced by herniated nucleus pulposus. J. Orthop. Res. 2001; 19: 472-7.
32. Trang T, McNaull B, Quirion R, Jhamandas K. Involvement of spinal lipoxygenase metabolites in hyperalgesia and opioid tolerance. Eur. J. Pharmacol. 2004; 491: 21-30.
33. 4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 1984; 225: 743-5.
34. Tonussi CR, Ferreira SH. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 1999; 82: 81-7.
35. Masferrer JL, Zweifel BS, Hardy M et al. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J. Pharmacol. Exp. Ther. 2010; 334: 294-301.
36. de Lima FO, Nonato FR, Couto RD et al. Mechanisms involved in the antinociceptive effects of 7-hydroxycoumarin. J. Nat. Prod. 2011; 74: 596-602.
37. Gilani AH, Janbaz KH, Shah BH. Esculetin prevents liver damage induced by paracetamol and CCL4. Pharmacol. Res. 1998; 37: 31-5.
38. 4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol. Biochem. Behav. 2010; 95: 41-50.
39. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 1957; 111: 409-19.
40. Bannon AW, Malmberg AB. Models of nociception: Hot-plate, tail-flick, and formalin tests in rodents. Curr. Protoc. Neurosci. 2007; 8: 9.
41. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32: 77-88.